BioNTech SE Class Action Lawsuit - BNTX

The filed complaint alleges that BioNTech SE made materially false and/or misleading statements and/or failed to disclose that: (i) BioNTech overstated demand for and/or the commercial prospects of Comirnaty, the COVID-19 vaccine developed by the Company in collaboration with Pfizer ; (ii) the Company and/or Pfizer had accumulated excess inventory of raw materials for Comirnaty, as well as COVID-19 vaccine doses adapted to other, non-XBB.1.5 variants that were produced at risk; (iii) accordingly, BioNTech was at an increased risk of recording significant inventory write-offs and other charges related to Comirnaty; and (iv) as a result, defendants’ public statements were materially false and/or misleading at all relevant times.

In order to be eligible to join the BNTX class action lawsuit, you must have incurred a loss on shares of BioNTech purchased during the class period listed above.

If you suffered a loss in BioNTech during the relevant time frame or pursuant to the relevant offering(s), you have until March 12, 2024 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.